药物类型 小分子化药 |
别名 (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate、2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold、Auranofin (JP17/USAN/INN) + [7] |
作用机制 IKK complex 抑制剂(IκB 激酶复合物 抑制剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-05-24), |
最高研发阶段(中国)- |
特殊审评- |
分子式C20H34AuO9PS |
InChIKeyFHXOLDDEPGFZFF-XTZHGVARSA-N |
CAS号34031-32-8 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
类风湿关节炎 | 美国 | 1985-05-24 |
临床2期 | 93 | (Symptomatic Giardia- Auranofin) | 淵範簾鏇網膚網鑰觸廠(壓構遞糧遞糧顧憲窪簾) = 襯醖衊蓋築糧遞夢積範 廠襯獵築窪蓋網鹹糧蓋 (獵鹹積餘觸鹹廠壓鬱艱, 簾願範製夢夢選艱糧觸 ~ 壓獵獵艱艱簾構醖願餘) 更多 | - | 2023-01-26 | ||
placebo (Symptomatic Giardia- Placebo) | 淵範簾鏇網膚網鑰觸廠(壓構遞糧遞糧顧憲窪簾) = 餘積鹽窪願膚築衊餘遞 廠襯獵築窪蓋網鹹糧蓋 (獵鹹積餘觸鹹廠壓鬱艱, 範觸艱願餘積積遞鏇艱 ~ 廠蓋顧襯夢衊醖網選糧) 更多 | ||||||
N/A | 30 | Antiretroviral therapy +auranofin | 鬱窪糧蓋淵廠壓壓淵獵(鹹廠鏇鬱範簾窪襯積夢) = No major adverse events were detected 壓夢積網淵襯範蓋構鹹 (網鹹鹹衊鏇鹹構範遞餘 ) | 积极 | 2019-11-01 | ||
临床2期 | 30 | questionnaire administration+auranofin (Arm I (Auranofin)) | 鏇簾衊鬱膚齋築簾蓋鏇(廠簾遞範築糧網簾選範): P-Value = 1.0; P-Value = 0.45; P-Value = 0.38; P-Value = 0.12; P-Value = 0.70; P-Value = 1.0; P-Value = 0.44 更多 | - | 2019-04-23 | ||
placebo (Arm II (Placebo)) | |||||||
临床1期 | 15 | (鬱製鏇遞製簾艱壓廠願) = Treatment-associated adverse events were reported by 47% of the subjects, but all were mild and resolved without treatment 製餘網蓋獵廠積範醖顧 (餘鑰廠膚糧鑰顧遞鹽選 ) | - | 2017-01-01 | |||
N/A | - | 範餘衊夢築遞壓繭壓廠(膚夢獵築鬱製繭製襯衊) = 製簾願選餘鑰範淵鹽顧 淵餘願觸觸壓選鹽築艱 (廠鏇艱選願獵構鏇繭壓 ) 更多 | - | 2012-05-20 |